Polatuzumab vedotin 140mg powder for solution for infusion vials
NHS hospitals in England used £115,875,399 of indicative cost of Polatuzumab vedotin 140mg powder for solution for infusion vials in the 12 months to July 2026, about 0.4% of all hospital medicines spend. That is up 1.8% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Polatuzumab vedotin 140mg powder for solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Polatuzumab vedotin 140mg powder for solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Western Sussex Hospitals Nhs Found Trust | £3,174,220 |
| Southend Univ Hosp Nhs Foundation Trust | £3,163,160 |
| Leeds Teaching Hpls Nhs Trust | £2,787,120 |
| United Lincolnshire Hospitals Nhs Trust | £2,731,820 |
| Univ Hpl B/Ham Nhs Foundation Trust | £2,643,340 |
| Sheffield Teaching Hospitals Nhs Trust | £2,377,900 |
| The Royal Marsden Nhs Foundation Trust | £2,289,420 |
| Cambridge Univ Hosp Nhs Foundation Trust | £2,123,520 |
| University College London Foundation Tr | £2,123,520 |
| Hull And East Yorkshire Hpls Nhs Trust | £2,023,980 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.